(571 Kb) [ High-Quality – 2027 ]

The search result you referenced is likely the , a PDF document exactly 571 KB in size, published by the U.S. Food and Drug Administration (FDA) .

This report is part of a series provided to Congress regarding the status of postmarketing requirements (PMRs) and postmarketing commitments (PMCs). Below is a summary based on the standard contents of these annual FDA backlog reports:

: Studies are categorized into "Pending" (not yet started), "Ongoing" (study underway), "Delayed" (behind the original schedule), or "Terminated/Released" (no longer required). (571 KB)

: A primary goal of the report is to demonstrate that the FDA is actively pushing for the completion of these studies to ensure long-term drug safety and efficacy. Other Possible Documents (571 KB)

: Mitsubishi Heavy Industries (MHI) lists a Corporate Governance report as part of its Integrated Report library with a size of 571 KB. The search result you referenced is likely the

: The UK government’s 2025-26 Government Financial Reporting Manual includes an "Agency Pink" PDF document at 571 KB.

: These reports typically track the number of open PMRs/PMCs, the percentage that are on schedule versus delayed, and the FDA's efficiency in reviewing the final study reports submitted by manufacturers. Below is a summary based on the standard

: The "backlog" specifically refers to older requirements and commitments that were established before certain regulatory modernizations (like those under the Food and Drug Administration Amendments Act of 2007). Common Findings in Recent Backlog Reports